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Protein threonine phosphorylationMitochondrial dysfunction is a major contributor in heart failure (HF). We investigated whether the decrease
in respirasome organization reported by us previously in cardiac mitochondria in HF is due to changes in the
phospholipids of themitochondrial inner membrane or modiﬁcations of the subunits of the electron transport
chain (ETC) complexes. The contents of the main phospholipid species, including cardiolipin, as well as the
molecular species of cardiolipin were unchanged in cardiac mitochondria in HF. Oxidized cardiolipin
molecular species were not observed. In heart mitochondria isolated from HF, complex IV not incorporated
into respirasomes exhibits increased threonine phosphorylation. Since HF is associated with increased
adrenergic drive to cardiomyocytes, this increased protein phosphorylation might be explained by the
involvement of cAMP-activated protein kinase. Does the preservation of cAMP-induced phosphorylation
changes of mitochondrial proteins or the addition of exogenous cAMP have similar effects on oxidative
phosphorylation? The usage of phosphatase inhibitors revealed a speciﬁc decrease in complex I-supported
respiration with glutamate. In saponin-permeabilized cardiac ﬁbers, pre-incubation with cAMP decreases
oxidative phosphorylation due to a defect localized at complex IV of the ETC inter alia. We propose that
phosphorylation of speciﬁc complex IV subunits decreases oxidative phosphorylation either by limiting the
incorporation of complex IV in supercomplexes or by decreasing supercomplex stability.niversity, School of Medicine,
veland, OH 44106–4981, USA.
el).
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The heart has a steady and uninterrupted requirement for energy
in the form of ATP produced by mitochondria. A link between a
decline in mitochondrial energy transduction and mechanical
dysfunction in heart failure (HF) is suggested by studies performed
in animal models [1,2] and in patients with genetic mitochondrial
diseases [3] or acquired cardiomyopathies [4–6]. In moderately severe
HF in dogs we found a 50% decrease in oxidative phosphorylation in
both populations of heart mitochondria, subsarcolemmal (SSM) and
interﬁbrillar (IFM) [7] without changes in either the content or
activities of individual electron transport chain (ETC) complexes. The
defect in oxidative phosphorylation is due to the decrease in the
amount of the supercomplex that consists of complex I/complex III
dimer/complex IV (I/III2/IV). This ﬁnding led to the conclusion that the
mitochondrial defect lies in respirasomes, and suggests either im-
paired formation or decreased stability.The ETC complexes, whether unincorporated in respirasomes or
organized in supercomplexes, are embedded in the phospholipid
bilayer structure of the mitochondrial inner membrane. Cardiolipin
(CL) is an anionic phospholipid present almost exclusively in the
mitochondrial inner membrane of eukaryotic cells. Tetra-linoleoyl-CL
[(C18:2)4-CL] is the predominant form of all CL species. The content of
(C18:2)4-CL is maintained by a continuous remodeling process under
the control of tafazzin (catalyzes the re-acylation reactions) and
mitochondrial phospholipase A (catalyzes the de-acylation reactions).
Cardiolipin provides structural and functional support to components
of both the mitochondrial ETC and phosphorylation apparatus [8–18].
Cardiolipin binding sites for all ETC components have been described,
and CL depletion results in reduced activities of complexes I, III [10]
and IV along with the dissociation of subunits VIa and IVb from
complex IV [19]. Mitochondrial dysfunction in the ischemic heart
[20,21] and HF [22] is reported to be associated with CL peroxidation,
loss of total CL content and decrease in (C18:2)4-CL.
Recent studies suggest that CL plays a central role in the higher
order organization of mitochondrial ETC in supercomplexes. It was
reported that CL is essential for either formation [23] or stabiliza-
tion [15] of respiratory supercomplexes. Yeast cells lacking Taz1, the
orthologue of human taffazin enzyme essential for CL remodeling,
revealed a decreased stability of the III2/IV2 supercomplex [24]. In
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syndrome), causes dilated cardiomyopathy associated with destabi-
lization of all supercomplexes containing complex IV, loss of complex I
from the supermolecular assembly and decrease of the individual
enzymatic activities of complexes I, III and IV [25].
There is an accumulating evidence that phosphorylation of mito-
chondrial proteins induced by cAMP/cAMP-activated protein kinase
(PKA) signaling pathway alters both the assembly [26–29] and the
activity of mitochondrial complexes [30]. In cardiomyocytes there are
two distinct cAMP generators, the transmembrane adenylyl cyclase
(AC) linked to β1-adrenergic receptors and activated by sympathetic
stimulation, and the mitochondrial soluble AC activated by calcium
and bicarbonate. Additional evidence shows that cardiac mitochon-
dria have a complete cAMP-PKA signaling pathway, with PKA present
on both mitochondrial membranes and matrix [31–39] and signal-
terminating mechanisms, such as phosphodiesterases [40] and
phosphatases [41,42] present in the matrix. cAMP/PKA-induced phos-
phorylation events that change the function of proteins occur on
components of all mitochondrial ETC complexes and phosphorylation
apparatus (for review see [30]), suggesting that cAMP represents a
major regulator of mitochondrial oxidative phosphorylation. Complex
IV seems to be the main target of this regulation. The allosteric control
of complex IV activity by intramitochondrial ADP/ATP ratio is
dependent on cAMP-induced phosphorylation of complex IV speciﬁc
subunits [43,44]. Phosphorylation of complex IV emerges as either
beneﬁcial or detrimental for complex IV activity. Phosphorylation of
complex IV subunits induced by overexpression of mitochondrial
soluble AC improves complex IV activity and mitochondrial respira-
tion in cultured cells and animals with complex IV deﬁciency [45]. In
contrast, PKA-dependent phosphorylation of complex IV in hypoxia
and cardiac ischemia causes a decrease in complex IV activity [46,47].
The two distinct effects on mitochondrial function may be explained
by the presence of two individual ACs and cAMP subcellular pools that
can be regulated differently in response to either extra- or intracel-
lular signals.
The aim of the present study was to identify the mechanism
responsible for the impaired supramolecular organization of the ETC
in cardiac mitochondria in HF. We hypothesized that the decrease in
the content of supercomplexes in HF is due either to 1) changes in the
phospholipid composition of the mitochondrial inner membrane or
to 2) postranslational modiﬁcations of the ETC complexes by phos-
phorylation. Our approach was ﬁrst to investigate the changes in the
main phospholipid species, including cardiolipin, and in themolecular
species of cardiolipin as potential causes of the decreased super-
complex amount in HF. Second, we investigated postranslational
modiﬁcations of mitochondrial proteins, speciﬁcally serine and
threonine phosphorylation in HF, a state which is associated with an
in vivo chronic stimulation of the β1-adrenergic receptors/transmem-
brane AC/cAMP/PKA signaling pathway in the heart. Third, to examine
the effect of acute activation of the mitochondrial PKA we used rat
cardiac ﬁbers incubated with membrane permeable cAMP. Fourth, by
preserving the phosphorylation status of mitochondrial proteins with
protein phosphatase inhibitors we studied the effect of increased
amount of phosphorylation changes on mitochondrial function.
2. Methods
2.1. Materials, reagents
Unless speciﬁed, all reagents were purchased from Sigma-Aldrich
and were of the highest purity grade.
2.2. Animal model
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health(NIH publication no. 85–23, revised 1996). All experimental protocols
were approved by the Case Western Reserve University Institutional
Animal Care and Use Committee. The intracoronary microemboliza-
tion-induced model as described [7,48,49] was used to induce HF in
dogs. Both groups were described in our previous study [7]. Male
Sprague–Dawley rats weighing 300–400 g were used to isolate car-
diac ﬁbers and cardiac mitochondria.
2.3. Isolation of cardiac mitochondria and ﬁbers
The dog heart SSM and IFM were isolated, studied and their
respiratory properties reported [7]. At that time, freshly-isolated
cardiac mitochondria were used for a comprehensive study of mito-
chondrial function in HF. A portion of each mitochondrial sample
was divided into small aliquots and stored at −60 °C until analyzed
in the current study. Rat cardiac SSM and IFM were isolated fol-
lowing the protocol of Palmer et al. [50] except that trypsin (5 mg/g
wet weight cardiac tissue) was used as a protease to isolate IFM. In
two experiments, both the isolation and storage buffers were
supplemented with protein phosphatase inhibitors (sodium ortho-
vanadate 1 mM, sodium ﬂuoride 10 mM, glycerophosphate 4 mM
and sodium diphosphate 1 mM). Mitochondrial protein concentra-
tion was determined by the Lowry method using bovine serum
albumin as a standard [51].
Individual heart muscle ﬁbers were obtained in high-energy
relaxing buffer (EGTA 10 mM, imidazole 20 mM, MES 50 mM,
dithiothreitol 0.5 mM, MgCl2 3 mM, ATP 5.77 mM, phosphocreatine
15 mM, pH 7.1) as described [52].
2.4. Measurement of respiratory properties of isolated cardiac
mitochondria and permeabilized ﬁbers
Oxygen consumption was measured in freshly-isolated intact
cardiac mitochondria with a Clark-type electrode as described [53,54]
and expressed as nA oxygen per minute per milligram mitochondrial
protein.
High-resolution respirometry was used to measure oxygen con-
sumption in permeabilized rat heart ﬁbers. Individual heart muscle
ﬁbers were permeabilized with saponin (50 μg/ml for 30 min at 4 °C)
and transferred into two chambers of an OROBOROS Oxygraph 2K
containing air-saturated assaymedium (EGTA 0.5 mM,MgCl2 3 mM, K
lactobionate 60 mM, taurine 20 mM, K phosphate 10 mM, HEPES
20 mM, sucrose 110 mM, bovine serum albumin 1 g/l) at 37 °C. Fibers
were incubated for 30 min with either assay buffer or assay buffer
supplemented with 200 μM dibutyryl cAMP to activate protein kinase
A (PKA) and 6.4 μM theophylline to inhibit phosphodiesterases and
maintain an increased cAMP content. Oxygen ﬂux in heart muscle
ﬁbers was assessed after sequential additions of substrates, ADP
(2.5 mM), dinitrophenol (uncoupler) and inhibitors, and expressed as
picomole O2 per seconds per milligram wet weight. The following
substrates were used: glutamate (10 mM)+malate (2 mM), succi-
nate (10 mM), and TMPD (5 mM)+ascorbate (2 mM).
2.5. Separation and quantitation of individual phospholipid species
Total lipids from frozen–thawed heart mitochondria of control
and HF dogs (1.5 mg mitochondrial proteins diluted to a ﬁnal volume
of 0.25 ml with 50 mM KCl) were extracted with chloroform/
methanol (3:1, by volume) [55]. Organic extracts were fractionated
by silica gel column chromatography into main lipid classes, which
were serially eluted using solvents of increasing polarity [56]. The
phospholipid (PPL) fraction was further separated by normal phase
high-performance liquid chromatography into different phospholipid
species and quantiﬁed by organic phosphate assay, as described [57].
Brieﬂy, the phospholipid fraction was collected in methanol. One
portion was used to measure the total organic phosphate in the PPL
1375M. Rosca et al. / Biochimica et Biophysica Acta 1807 (2011) 1373–1382fraction and another portion was subjected to normal-phase HPLC
performed on a Hypersil silica column (4.6×250 mm, 5 μm). Elution
was performed with an initial mobile phase of hexane:2-propa-
nol:25 mM potassium acetate (pH 7.0):ethanol:glacial acetic acid
(367:490:62:100:0.6, by volume) followed by a gradient (increasing
hexane and decreasing ethanol) to the mobile phase. The individual
chromatographic peaks noted in Table 1 were identiﬁed by compar-
ison of retention times of standards.
Organic phosphate was measured by reading the absorbance in a
plate reader at 815 nm. The recovery was calculated as a percentage of
the sum of individual PPL species (total phosphate in the PPL, total PPL
in Table 1) from the total organic phosphate (the starting material).
2.6. Separation and quantitation of cardiolipin molecular species
Reversed-phase ion pair high performance liquid chromatography-
mass spectrometry was used to separate, identify and quantify the CL
molecular species as described [58].
2.7. Separation of mitochondrial supramolecular complexes by Blue
Native PAGE electrophoresis and Western blot analysis
BN-PAGE was performed following the general approach of
Schagger and Wittig [59]. Three hundred micrograms of the stored
mitochondrial proteins were extracted with digitonin (detergent:
protein ratio of 6:1 g/g) for 30 min at 4 °C in solubilization buffer
(imidazole 50 mM, NaCl 50 mM, 6-aminocaproic acid 2 mM, EDTA
1 mM, pH 7.0), combined with Coomassie blue G-250 dye (detergent/
dye ratio of 8:1 g/g), and separated on precast 3%–12% acrylamide–
bisacrylamide gradient gels (Invitrogen NativePAGE minigels) at
75 μg proteins per well. Proteins were electroblotted onto PVDF
membranes and probed with either phosphoserine or phosphothreo-
nine antibodies (Santa Cruz Biotechnology, 1:5000 dilution). Appro-
priate HRP-linked secondary antibodies were used (BioRad, 1:10,000
dilution). Membranes were developed using Amersham ECL™ sub-
strates. Densitometric evaluation of the gels was carried out using
Image J from the National Institutes of Health and Multi Gauge V3.0
from Fujiﬁlm Life Science.
2.8. Statistical analysis
The results were analyzed using the student's 2 tailed-t test except
the data in Figs. 4 and 5. Data are reported as mean±SEM. To be
considered signiﬁcant, the p value had to be less than 0.05.
Linear statistical models were ﬁtted to the data in Figs. 4 and 5 to
obtain p values for difference parameters. For variance stabilizationTable 1
Content of phospholipids in heart subsarcolemmal (SSM) and interﬁbrillar (IFM)
mitochondria from control and HF dogs (nanomole phospholipid phosphate per
milligram mitochondrial protein). Mean±SEM. PE, phosphatidylethanolamine; PI,
phosphatidylinositol; CL, cardiolipin; PC, phosphatidylcholine.
Control Heart failure P values
PE 90±7 110±13 0.29
PI 12±2 18±2 0.08
CL 42±4 49±6 0.50
PC 130±8 177±22 0.16
Total PPL 274±20 353±38 0.19
Total organic phosphate 273±30 346±16 0.08
Recovery (%) 102±14 106±15 0.96
Heart IFM N=5 N=4
PE 95±5 118±8 0.09
PI 15±3 18±4 0.42
CL 51±4 52±7 0.89
PC 151±7 189±9 0.03
Total PPL 311±15 376±21 0.08
Total organic phosphate 366±30 369±34 0.96
Recovery (%) 85±6 101±4 0.08the Box–Cox transformation was used with λ=0.52 (Fig. 4) and 0.23
(Fig. 5) set per the R function box–cox in the R package MASS: λ=0
corresponds to a log, λ=0.5 to a square root, and λ=1 to no
transformation. Quantile–quantile and residual-versus-ﬁtted-value
plots were used to conﬁrm the normality assumptions of the models.
3. Results
The hemodynamic parameters of control dogs and dogswith HF, as
well as the respiratory properties and the amount of free ETC
complexes and of the I/III2/IV1 respirasome in cardiac mitochondria,
were reported elsewhere [7]. In brief, repeated coronary microem-
bolization in dogs caused a progressive and moderately severe
worsening of the left ventricle (LV) performance manifested as a
decrease in ejection fraction (from 34±1 to 28±1) and increases in
the LV end-systolic volume (from 42±1 to 47±1 ml) and end-
diastolic volume (from 64±2 to 67±2 ml) [7].
3.1. Separation and quantitation of individual phospholipid species
The content of mitochondrial phospholipids (phosphatidyletha-
nolamine, phosphatidylinositol, CL and phosphatidylcholine) is given
in Table 1. The analytical accuracy of these determinations is
highlighted by the recovery of phospholipids that averaged 85%–
100%. The amount of phosphatidylcholine is increased in HF whereas
the amount of CL is not changed. Our data rule out the alteration in the
total content of mitochondrial CL as a cause for the decrease in the
supercomplex assembly in HF.
3.2. Separation and quantitation of cardiolipin molecular species
Cardiolipin separated by normal phase HPLC was characterized by
reverse-phase ion-pair HPLC coupled with a hybrid triple quadruple
linear ion-trap MS. Molecular species of CL from cardiac SSM and IFM
of control dogs and dogs with HF were separated and their molecular
mass identiﬁed. The percentage of CL species was determined from
total CL content. Fig. 1A and B show the total ion chromatograms of
the CL molecular species eluting between 15 and 40 min. Unmodiﬁed
tetra-linoleoyl-CL [(C18:2)4-CL] elutes at ~30 min, and was the
predominant CL species in heart SSM and IFM isolated from both
control dogs and dogs with HF (Fig. 1A and B, and Table 2). The
proportional amount of (C18:2)4-CL was not changed in cardiac
mitochondria isolated from HF compared with the control hearts.
Oxidation products of CL, shown to elute earlier than the unmodiﬁed
CL [60] due to their decreased hydrophobicity, are not observed in HF
in either cardiac SSM or IFM. Other CL species identiﬁed were tri-
linoleoyl-mono-oleoyl-CL [(C18:2)3, (C18:1)], di-linoleoyl-di-oleoyl-
CL [(C18:2)2(C18:1)], tri-linoleoyl-mono-palmitoleoyl-CL [(C18:2)3
(C16:1)] and tri-linoleoyl-mono-linolenoyl-CL [(C18:2)3(C18:3)1]
(Fig. 1A and B); the amount of those species did not change in cardiac
mitochondria isolated from HF compared to those isolated from
control dogs. We conclude that alteration in the mitochondrial CL
species and acyl composition is not the cause of the decrease in
supercomplex content in moderately severe HF in dogs.
3.3. Separation of mitochondrial supramolecular complexes by Blue
Native PAGE electrophoresis and Western blot analysis
We compared the status of phosphorylation at serine (Fig. 2) and
threonine (Fig. 3) residues of supercomplexes and complexes not
incorporated within the main respirasome (I/III2/IV) in cardiac mito-
chondria from control and HF dogs. There is a large variability in the
amount of both serine and threonine modiﬁcations especially on
proteins assembled in supercomplexes in cardiac SSM isolated from
HF dogs. This may be a reﬂection of either the variability of phos-
phorylation modiﬁcations on mitochondrial proteins from this
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Fig. 1. Representative total ion chromatograms generated from cardiac SSM (A) and IFM (B) isolated from control dogs and dogs with HF.
1376 M. Rosca et al. / Biochimica et Biophysica Acta 1807 (2011) 1373–1382experimental group or the loss of phosphorylation modiﬁcations due
to mitochondrial phosphatases during the freezing-thawing proce-
dure. The levels of phosphorylation at both serine and threonine
residues I/III2/IV supercomplex were signiﬁcantly decreased in heart
IFM isolated from HF, with a similar trend in heart SSM. These results
are in agreement with the decreased amount of the supercomplex in
HF in both types of cardiac mitochondria.As shown in Fig. 3, complex IV unincorporated in the super-
complex contained a signiﬁcant increased content of threonine
phosphorylation in both types of heart mitochondria isolated from
HF compared to the control. Since there is a pronounced activation
of the β-adrenergic stimulation in cardiomyocytes in HF, our data
suggest that cyclic AMP may have a role in phosphorylation of com-
plex IV subunits at threonine residues. We also detected threonine
Table 2
Cardiolipin species in heart subsarcolemmal (SSM) and interﬁbrillar (IFM) mitochon-
dria from control and HF dogs. Results are expressed as percentage of total cardiolipin
content. Mean±SEM. The abbreviations are in section 3.2.
Heart SSM Control Heart failure
N=6 N=5
(C18:2)4 77.5±1.2 80.7±3.0
(C18:2)3 (C18:1)1 13.4±0.7 13.3±1.4
(C18:2)2(C18:1)2 3.9±0.1 3.0±0.9
(C18:2)3 (C16:1)1 3.7±0.3 2.1±1.0
(C18:2)3 (C18:3)1 1.5±0.2 0.9±0.1
Heart IFM N=4 N=6
(C18:2)4 79.5±0.8 80.3±2.2
(C18:2)3 (C18:1)1 12.1±0.3 13.6±1.0
(C18:2)2 (C18:1)2 3.7±0.2 2.9±0.7
(C18:2)3 (C16:1)1 3.3±0.3 2.1±0.7
(C18:2)3 (C18:3)1 1.4±0.1 1.0±0.2
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differ between mitochondria from control hearts and heart with HF.
Our procedure did not detect any threonine phosphorylation in
complex V.
In contrast, the level of phosphorylation at serine of subunits of
complex IV unincorporated within the respirasome was not changed
in cardiac mitochondria isolated from HF compared with the control
(Fig. 2). Complex III unincorporated in supercomplexes has a large
amount of serine phosphorylation in both SSM and IFM isolated from
control heart and the amount is not changed by HF.
3.4. The effect of protein phosphorylation on mitochondrial function
3.4.1. The effect of protein phosphatase inhibitors (PPI)
In order to preserve the steady-state level of phosphorylation by
preventing the action of phosphatases in removing the phosphate
group from mitochondrial proteins, we isolated the two populations
of rat cardiac mitochondria with protein phosphatase inhibitors (PPI)SSM. 
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Fig. 2. (A) Western blot analysis of supercomplexes and individual complexes of heart SSM
Densitometric analysis. *pb0.05 control vs HF. Mean±SEM.present in the isolation and storage buffers. ADP-dependent oxidative
phosphorylation rates (state 3 rates) of rat heart SSM and IFM isolated
and stored in the presence of PPI were compared with state 3
respiratory rates of rat heart mitochondria without PPI. Mitochondria
isolated and investigated in the presence of PPI showed a decrease in
the respiratory state 3 rates with complex I substrate glutamate
(p=0.0003 and 0.0001 for SSM and IFM, respectively), while the
oxidative rates with complex II (succinate), III (duroquinol) and IV
(TMPD+ascorbate) substrates are unchanged (Fig. 4). Uncoupling
does not restore respiration, showing that the defect is localized at the
level of oxidation side of oxidative phosphorylation rather than in the
ATP-synthesis machinery. Moreover, the preservation of the steady-
state level of phosphorylation on mitochondrial proteins with PPI
does not change the amount of respirasomes in both populations of
rat heart mitochondria (data not shown). Therefore, the addition of
PPI reveals a selective defect in glutamate-supported respiration at
the level of either glutamate transporter, glutamate dehydrogenase,
or complex I.
3.4.2. The effect of exogenously-added cyclic AMP on mitochondrial
oxidative phosphorylation
High-resolution respirometry was used to investigate the effect of
cAMP on mitochondrial oxidative phosphorylation in saponin-
permeabilized rat heart ﬁbers (Fig. 5). The respiratory rate with
complex I substrates glutamate+malate in the absence of ADP is not
changed by cAMP. The ADP-dependent (state 3) respiratory rates of
cAMP-incubated ﬁbers in the presence of complex I substrates
(electron transport through complexes I/III/IV) was 70% of the control
cardiac ﬁbers. Respiratory rates did not signiﬁcantly increase upon the
addition of cytochrome c, showing that the high mitochondrial outer
membrane integrity of cardiac ﬁbers is maintained in the presence
of cAMP. The addition of succinate (electron input to complex II)
resulted in an increase in oxygen consumption in the control (80%)
with a much smaller increase in the cAMP-incubated ﬁbers (27%).
Therefore, the oxygen ﬂux through complexes I+II/III/IV in the
cAMP-incubated ﬁbers was approximately 50% of the control.IFM.
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Fig. 3. (A)Western blot analysis of supercomplexes and individual complexes of heart SSM and IFM isolated by BN PAGE and probed with threonine phosphorylation antibodies. (B)
Densitometric analysis. *pb0.05 control vs HF. Mean±SEM.
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357.4 pmol/s/mg wet weight in control and cAMP-incubated ﬁbers,
respectively), showing that the defect induced by cAMP resides
within a component of the oxidative side of oxidative phosphoryla-
tion and not in the phosphorylation apparatus.
Oxygen ﬂux through complexes II/III/IV in the cAMP-incubated
ﬁbers measured upon the addition of rotenone was 33% of the
control (140.6 vs 421.2 pmol/s/mg wet weight in cAMP-incubated
ﬁbers and control, respectively). These data indicate a greaterA
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were measured with 200 μM dinitrophenol. Abbreviations: TMPD, N,N,N′,N′-tetramethyl-p-p
independent experiments. *pb0.05 control vs HF. Mean±SEM.inhibition by cAMP of complex II-supported respiration than of
complex I-supported respiration, in contrast with the major effect of
PPI on complex I-driven respiration, with preservation of respiration
initiated by the complex II substrate (Fig. 4). Subsequent inhibition
of complex III with antimycin A blunted the oxygen ﬂux in both
samples. TMPD+ascorbate donates reducing equivalents to cyto-
chrome c, which is then oxidized by cytochrome c oxidase with ﬁnal
tetravalent reduction of oxygen to water. Incubation with cAMP
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incubated ﬁbers, respectively). Azide blunted the oxygen ﬂux in both
samples. In conclusion, cAMP leads to a decrease in oxidative
phosphorylation with complex I, II and IV substrates, suggesting
defects in the ETC localized at least at the level of cytochrome c oxidase.
4. Discussion
We recently reported that the 50% reduction in oxidative
phosphorylation of cardiac mitochondria in moderately severe HF
may be explained by ~30% and 50% decrease in the amount of the
major mitochondrial I/III2/IV1 respirasome in cardiac SSM and IFM,
respectively [7]. We concluded that the mitochondrial defect in HF
either limits the incorporation of individual complexes in super-
complexes or enhances supercomplex degradation. In follow-up to
our previous study, we asked if the decrease in the supercomplex
content is due to changes in the phospholipids of the mitochondrial
inner membrane or postranslational modiﬁcations of subunits of the
ETC complexes. The primary ﬁndings of the present study are: 1) the
amount of total phospholipids did not change in both cardiac SSM and
IFM isolated from HF compared with the control; 2) from phospho-
lipid species, phosphatidylcholine is increased in HF whereas the
amount of cardiolipin does not change; 2) (C18:2)4-CL represents the
most abundant CL species, making up more than 80% of the total CL in
both cardiac SSM and IFM isolated from control dogs and dogs with
HF; 3) there were no changes in the content of (C18:2)4-CL in both
cardiac SSM and IFM; 4) the amount of minor CL species also did not
change in HF in both populations of cardiac mitochondria; 5) no
oxidized CL species were observed in HF; 6) complex IV not incor-
porated into the respirasome organization exhibits a signiﬁcant
increase in threonine phosphorylation in heart mitochondria isolated
from HF compared with the control. These data indicate that the
damage of the ETC assembly in this model of HF of moderate severity
is not due to changes in the CL proﬁle, and suggest that cAMP-
dependent phosphorylation at threonine residues of mitochondrial
proteins may play a role. We next asked if either exogenously-added
cAMP or preservation of the cAMP-induced phosphorylation of
mitochondrial proteins have similar effects on mitochondrial oxida-
tive phosphorylation. We found that both approaches reveal defects
localized in the oxidative side of oxidative phosphorylation rather
than in the ATP-synthesis machinery. In permeabilized cardiac ﬁbers,
cAMP causes a decrease in oxidative phosphorylation due to defect(s)
localized at least at the level of cytochrome c oxidase. In contrast, the
preservation of the steady-state level of phosphorylation on mito-
chondrial proteins with protein phosphatase inhibitors reveals defect
(s) localized at either glutamate transporter, glutamate dehydroge-
nase, or complex I.
ETC complexes are assembled into high-molecular weight super-
complexes [61,62] which represent the structural basis for oxidative
phosphorylation. In the I1III2IV1 supercomplex (respirasome) thatcontains coenzyme Q and cytochrome c, the electron carriers are
closely apposed [63], supporting the concept of channeled electron
transfer from NADH to reduce oxygen [64], decreasing electron
leakage and superoxide production [65]. The individual complexes are
ﬁxed in this cohesive respiratory unit by either protein-lipid and/or
protein-protein interactions. Although the concept suggested by
Skulachev [66] that cardiolipin is a major factor for supercomplex
stability was conﬁrmed in yeast [23], further studies showed that CL is
not essential for the formation of supercomplexes in the inner mem-
brane, but stabilizes the ETC supercomplexes and individual com-
plexes in yeast [15] and humans [25]. Cardiolipin facilitates speciﬁc
protein-protein interactions by providing ionic bridges at the hydro-
phobic interfaces of the subunits of individual complexes, and by
adjusting irregular protein surfaces into ﬂexible interfaces, thus
allowing the interaction between less tightly-associated proteins [23].
We report a decrease in the amount of the I1III2IV1 respirasome
which is not associated with changes in either the content of total CL
or CL molecular species proﬁle in HF of moderate severity. Tetra-
linoleoyl-CL is the predominant CL in both populations of cardiac
mitochondria isolated from HF, suggesting that the tafazzin-
dependent remodeling step of CL is not altered in HF. These data
differ from those reported for other models of HF by Sparagna et al.
who found a decrease in the amount of [(C18:2)4]CL in animals with
accelerated hypertensive HF [67] and humans with severe HF [22],
associated with a decline in complex IV activity with unchanged
complex amount. The authors, however, did not investigate the parti-
tion of complex IV, as part of the I1III2IV1 respirasome or unincor-
porated within the supercomplex. Our data generated in a less severe
stage of HF in dogs indicate that the decrease in functional
respirasomes is independent of both the mitochondrial CL content
and CL molecular species proﬁle and point to speciﬁc protein/protein
interactions between subunits of individual complexes as a cause for
the decrease in supercomplex content.
We further asked if the primary event causing the defect in the
ETC assembly is represented by modiﬁcations of protein subunits of
ETC complexes. Phosphorylation seems to be a frequent postransla-
tional modiﬁcation in mitochondrial proteome. More than 60 mito-
chondrial proteins are phosphoproteins [68] and at least half are
phosphorylated at serine and threonine residues. The increased adre-
nergic drive in HF implies a pronounced activation of the β-adrenergic
receptor-stimulatory GTP-binding protein-adenylyl cyclase-cAMP
signaling pathway in cardiomyocytes. Several observations provide
the basis for a speciﬁc mitochondrial cAMP-protein kinase A (PKA)
signaling pathway: 1) there are high concentrations of cAMP in
mitochondria [69] that further increase within 2–3 min upon
activation of β-adrenergic receptors by isoproterenol [70]; 2) the
soluble mitochondrial adenyl cyclase regulates oxidative phosphor-
ylation [40]; and 3) PKA is present in mitochondria [34–39].
As a ﬁrst step in deﬁning the role of cAMP-dependent phosphor-
ylation in the decrease of the respirasome organization in HF, we
compared the level of phosphorylation at serine and threonine resi-
dues of the main respirasome and of individual complexes in cardiac
mitochondria isolated from control dogs and dogs with HF. We found
that complex IV unincorporated in the supercomplex has a signiﬁcant
increase in the content of threonine phosphorylation in both types of
heart mitochondria isolated from HF compared with the control. We
also detected threonine phosphorylation on complexes III and I, but
the content did not differ between mitochondria from control hearts
and hearts with HF. We did not detect threonine phosphorylation in
complex V, showing that complex V is not a major target for this
substrate-speciﬁc phosphorylation.
Phosphorylation controls complex IV activity and stability. Cyclic
AMP-dependent phosphorylation at Tyr-304 on helix VIII of COX
subunit I [71] causes a strong allosteric inhibition in the presence of
ATP with no activity at physiologic levels of cytochrome c, when
mitochondria were isolated in the presence of the phosphodiesterase
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causes cAMP-induced phosphorylation of COX subunits I (Ser115/
Ser116), IV (Thr52) and Vb (Ser40) [46] and increases reactive oxy-
gen species production [47] by rabbit heart mitochondria isolated
without protein phosphatase inhibitors. These serine phosphorylation
sites in subunits IV and Vb apparently are not related to the regula-
tion of COX activity, and it was suggested that they are involved in
the binding afﬁnity of COX with other proteins and COX incorpora-
tion in supercomplexes [72]. The increased threonine phosphoryla-
tion of the unincorporated complex IV in mitochondria isolated from
HF in the absence of both phosphodiesterase and phosphatase
inhibitors does not change the individual activity of complex IV
which was reported in our previous study [7]. The data suggest that
these threonine phosphorylation modiﬁcations involve small regula-
tory subunits of complex IV rather than catalytic subunits. Unfortu-
nately, the exhaustion of mitochondrial supply limited the depth of
the present study in identifying the speciﬁc subunits of complex IV
that are phosphorylated.
In our experiments, both electrophoretic separation of super-
complexes and Western blot analysis were performed with −60 °C
frozen/thawed mitochondria. Therefore, the post-translational mod-
iﬁcations we detected in cardiac mitochondria in both Control and HF
are stable ex vivo upon storage and freezing/thawing procedures and
represent the steady-state level of phosphorylation events.
The level of phosphorylation on mitochondrial proteins is under
the control of protein kinases including PKA and the activity of
mitochondrial phosphatases. We asked if the increasedmitochondrial
content of cAMP or preservation of the cAMP-induced phosphoryla-
tion of mitochondrial proteins have similar effects on mitochondrial
oxidative phosphorylation. The content of cAMP within the mito-
chondria is balanced by its potential import from the cytosol and
mitochondrial synthesis on one hand, and its degradation via mito-
chondrial phosphodiesterases on the other. Cyclic AMP released from
the membrane-permeable dibutyryl cAMP by cellular esterases was
used to increase the content of cAMP in mitochondria from saponin-
permeabilized cardiac ﬁbers in the presence of a phosphodiesterase
inhibitor. Exogenously-added cAMP leads to a 50% decrease in
oxidative phosphorylation through complex I+II/III/IV in rat cardiac
ﬁbers, suggesting defect(s) in the ETC localized at least at the level of
complex IV. The analysis of the effect of cAMP on oxidative phos-
phorylation of mitochondria in situ in permeabilized rat heart ﬁbers
yields similar results as the investigation of oxidative phosphoryla-
tion in isolated mitochondria in HF [7]. When the pathway was dis-
sected, we found that respiration through complexes II/III/IV is
decreased to a greater extent than the respiration through complexes
I/III/IV, suggesting an additional defect of the succinate transporter or
complex II.
In our experiments, dog mitochondria were isolated and stored in
the presence of the Ca2+ chelator EGTA that disables the Ca2+-
dependent phosphatases in the absence of broad-spectrum protein
phosphatase inhibitors. We therefore checked if we uncovered only
an incomplete picture of phosphorylation events on mitochondrial
proteins in both control heart mitochondria and in mitochondria
isolated from dogs with HF due to the removal of the phosphate group
from proteins by mitochondrial phosphatases during the mitochon-
drial isolation and storage. Interestingly, the addition of phosphatase
inhibitors reveals a selective decrease in glutamate-supported respi-
ration due to defect(s) located at the level of the substrate transport
and processing (glutamate transporter and dehydrogenase) or com-
plex I, with preservation of respiration driven by complex II, III and
IV substrates.
Both approaches used to investigate the effect of protein
phosphorylation on mitochondrial function led to the conclusion
that the ATP-synthesis machinery (ATP synthase, adenine nucleotide
translocase, and phosphate transporter) is not a target for functional
changes induced by cAMP. This conclusion is congruent with theabsence of serine and threonine phosphorylation in complex V in
cardiac mitochondria isolated from both control and HF dogs. Both
approaches instead point to changes in the oxidation side of oxidative
phosphorylation located at different sites. However, since the oxi-
dation of complex I substrates glutamate+malate depend upon the
integrity of complex IV, we cannot exclude additional defects in either
substrate processing or complex I upon the addition of exogenous
cAMP on cardiac ﬁbers. Speciﬁc changes in glutamate transporter and
dehydrogenase may be induced by irreversible phosphorylation
events due to the artiﬁcial inhibition of mitochondrial phosphatases.
In addition, orthovanadate, used by us in the protein phosphatase
inhibitor cocktail, also was reported to inhibit mitochondrial gluta-
mate dehydrogenase [73] and succinyl CoA synthase [74], suggesting
that phosphatase inhibitors lead to defects in glutamate-supported
mitochondrial respiration that may be independent of protein
phosphorylation. Alternatively, the unchanged complex IV-supported
respiration upon preservation of protein phosphorylation events
induced by a base-level of mitochondrial cAMP suggests that the
defect in complex IV may be revealed only by elevated mitochondrial
cAMP content.
Based on our observations, we propose that in HF cAMP, either
generated by the β-adrenergic receptor-linked adenylyl cyclase in
cardiomyocytes or synthesized by soluble adenylyl cyclase in mito-
chondria, activates the mitochondrial PKA which phosphorylates
threonine residues on subunits of complex IV. These postranslational
modiﬁcations either impair the incorporation of complex IV into
supercomplexes or cause the release of complex IV from the super-
complex, reducing the amount of functional respirasomes and de-
creasing the oxidative phosphorylation of heart mitochondria.
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